About Hepatic Encephalopathy (HE) Therapeutics
HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
Technavio’s analysts forecast the global hepatic encephalopathy (HE) therapeutics market to grow at a CAGR of 5.35% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global hepatic encephalopathy (HE) therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Hepatic Encephalopathy (HE) Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• ASKA Pharmaceutical
• COSMO PHARMACEUTICALS
• Mallinckrodt
• Valeant
Market driver
• Availability of patient-focused programs to assist disease management
• For a full, detailed list, view our report
Market challenge
• Late and inaccurate diagnosis
• For a full, detailed list, view our report
Market trend
• Technological advances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE ANALYSIS
PART 09: MARKET SEGMENTATION BY PRODUCT
• Overview
• Comparison by product
• NADs
• Antibiotics
• Others
• Market opportunity by product
PART 10: MARKET SEGMENTATION BY DISEASE SEVERITY
• Overview
• CHE
• OHE
PART 11: CUSTOMER LANDSCAPE
PART 12: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas
• EMEA
• APAC
• Key leading countries
• Market opportunity
PART 13: DECISION FRAMEWORK
PART 14: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 15: MARKET TRENDS
• Technological advances
• Emergence of novel treatment targets
PART 16: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 17: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ASKA Pharmaceutical
• COSMO PHARMACEUTICALS
• Mallinckrodt
• Valeant
PART 18: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Interorgan ammonia metabolism in healthy liver
Exhibit 02: WHC classification of HE
Exhibit 03: Recommended treatment pathway for HE
Exhibit 04: Parent market
Exhibit 05: Global CNS disorders drugs market: Segments
Exhibit 06: Market characteristics
Exhibit 07: Global HE therapeutics market: Segments
Exhibit 08: Market definition: Inclusions and exclusions checklist
Exhibit 09: Market size 2017
Exhibit 10: Validation techniques employed for market sizing 2017
Exhibit 11: Global HE therapeutics market 2017-2022 ($ millions)
Exhibit 12: Global HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition: Five forces 2017
Exhibit 21: Pipeline landscape by development phase
Exhibit 22: Key clinical trials
Exhibit 23: Global HE therapeutics market: Segmentation by product 2017-2022 (%)
Exhibit 24: Comparison by product
Exhibit 25: Global NAD HE therapeutics market 2017-2022 ($ millions)
Exhibit 26: Global NAD HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 27: Global antibiotic HE therapeutics market 2017-2022 ($ millions)
Exhibit 28: Global antibiotic HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 29: Global other HE therapeutics market 2017-2022 ($ millions)
Exhibit 30: Global other HE therapeutics market: Year-over-year growth 2018-2022 (%)
Exhibit 31: Market opportunity by product
Exhibit 32: Customer landscape
Exhibit 33: Global HE therapeutics market: Segmentation by geography 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: HE therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 36: HE therapeutics market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 37: HE therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 38: HE therapeutics market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 39: HE therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 40: HE therapeutics market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: ASKA Pharmaceutical: Overview
Exhibit 49: ASKA Pharmaceutical: Business segments
Exhibit 50: ASKA Pharmaceutical: Organizational developments
Exhibit 51: ASKA Pharmaceutical: Segment focus
Exhibit 52: ASKA Pharmaceutical: Key offerings
Exhibit 53: ASKA Pharmaceutical: Key customers
Exhibit 54: COSMO PHARMACEUTICALS: Overview
Exhibit 55: COSMO PHARMACEUTICALS: Business segments
Exhibit 56: COSMO PHARMACEUTICALS: Organizational developments
Exhibit 57: COSMO PHARMACEUTICALS: Segment focus
Exhibit 58: COSMO PHARMACEUTICALS: Key offerings
Exhibit 59: COSMO PHARMACEUTICALS: Key customers
Exhibit 60: Mallinckrodt: Overview
Exhibit 61: Mallinckrodt: Business segments
Exhibit 62: Mallinckrodt: Organizational developments
Exhibit 63: Mallinckrodt: Geographic focus
Exhibit 64: Mallinckrodt: Segment focus
Exhibit 65: Mallinckrodt: Key offerings
Exhibit 66: Mallinckrodt: Key customers
Exhibit 67: Valeant: Overview
Exhibit 68: Valeant: Business segments
Exhibit 69: Valeant: Organizational developments
Exhibit 70: Valeant: Geographic focus
Exhibit 71: Valeant: Segment focus
Exhibit 72: Valeant: Key offerings
Exhibit 73: Valeant: Key customers
